• In late February 2026, Catalyst Pharmaceuticals reported fourth quarter 2025 revenue of US$152.61 million and full-year 2025 revenue of US$588.99 million, alongside earnings guidance for full-year 2026 of US$615 million to US$645 million.
• These results highlight how expanding rare-disease franchises like FIRDAPSE and AGAMREE are becoming increasingly important profit drivers for the company.
• We’ll now examine how Catalyst’s raised 2026 revenue outlook reshapes its existing investment narrative and risk‑reward profile for investors.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

Catalyst Pharmaceuticals Investment Narrative Recap

To own Catalyst Pharmaceuticals, you need to believe in the durability of its rare disease franchises and their ability to offset concentration and patent risks tied to FIRDAPSE. The raised 2026 revenue outlook to US$615 million to US$645 million supports the near term growth story, but does not remove the key risks around potential FIRDAPSE generic entry and a relatively thin late stage pipeline.

The 2026 guidance update is the clearest recent data point for investors, because it links record 2025 revenue of US$588.99 million with management’s confidence in continued product revenue growth. It also reinforces how much the current thesis leans on further uptake of FIRDAPSE and AGAMREE, at a time when FYCOMPA faces generic headwinds and legal outcomes around FIRDAPSE exclusivity remain important watch items.

Yet this improved outlook sits alongside legal and patent uncertainties around FIRDAPSE that investors should be aware of, especially if...

Catalyst Pharmaceuticals’ narrative projects $709.1 million revenue and $253.5 million earnings by 2028. This requires 8.3% yearly revenue growth and about a $44.8 million earnings increase from $208.7 million today.

Uncover how Catalyst Pharmaceuticals' forecasts yield a $34.29 fair value, a 41% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community range from US$23.92 to US$63.39, underlining how far apart individual views can be. Against that spread, the company’s higher 2026 revenue guidance sharpens the focus on whether FIRDAPSE driven growth can continue to support current margins and offset concentration risk over time.

Explore 10 other fair value estimates on Catalyst Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Catalyst Pharmaceuticals research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Catalyst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Catalyst Pharmaceuticals' overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 16 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.